Company OliX Pharmaceuticals, Inc

Equities

A226950

KR7226950004

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 23:00:00 25/04/2024 BST			5-day change	1st Jan Change
15,220 ^KRW	-0.59%		+1.67%	+4.39%

03-22	OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors	CI
03-20	OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors	CI

OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Companyâs product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.

KRW in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	9,320	100.0 %	17,064	100.0 %	+83.09%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	9,320	100.0 %	17,064	100.0 %	+83.09%

Managers	Title	Age	Since
Dong-Gi Lee FOU	Founder	52	31/01/10
Jun-Hyun Park CTO	Chief Tech/Sci/R&D Officer	39	-
Young-Hye Baek BRD	Director/Board Member	49	-
Chung-Gil Kang BRD	Director/Board Member	53	-
Sin-Young Park BRD	Director/Board Member	59	-
Sung-Hwa Hong AUD	Comptroller/Controller/Auditor	67	-

Members of the board	Title	Age	Since
Yang-Gyoon Kim BRD	Director/Board Member	57	-
Chang-Soo Yoon BRD	Director/Board Member	51	-
Dong-Gi Lee FOU	Founder	52	31/01/10
Sin-Young Park BRD	Director/Board Member	59	-
Chung-Gil Kang BRD	Director/Board Member	53	-
Young-Hye Baek BRD	Director/Board Member	49	-

	Vote	Quantity	Free-Float	Total Float
Stock A	0	442,128	0	73.23 %
Stock B	1	16,526,595	12,102,177 ( 73.23 %)
Stock C	0	431,583	0

Name	Equities	%	Valuation
Dong-Gi Lee 20.99 %	3,455,160	20.99 %	43 M ₩
Mirae Asset Global Investments Co., Ltd. 5.726 %	942,614	5.726 %	12 M ₩
National Pension Service of Korea 5.225 %	860,000	5.225 %	11 M ₩
So-yun Kim 2.427 %	399,528	2.427 %	5 M ₩
HUGEL, INC. 2.160 %	355,592	2.160 %	4 M ₩
Kiwoom Investment Co., Ltd. 1.065 %	175,324	1.065 %	2 M ₩
Sun-Woo Hong 0.3788 %	62,348	0.3788 %	771 101 ₩
Byung-Seok Lee 0.3645 %	60,000	0.3645 %	742 061 ₩
Chung-Gil Kang 0.3645 %	60,000	0.3645 %	742 061 ₩
Sin-Young Park 0.2430 %	40,000	0.2430 %	494 708 ₩

Name	Equities	%	Valuation
PCL, INC. 7.65%	4,132,665	7.65%	4,475,718 $

OliX Pharmaceuticals, Inc.

#1014 Ace Gwangkyo Tower1 17 Daehak 4-ro

16226, Suwon-si

http://www.olixpharma.com

address OliX Pharmaceuticals, Inc(A226950)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
OLIX PHARMACEUTICALS, INC	+4.39%	183M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.82%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.21%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs